Vanguard Investments Australia
DMRA

Vanguard Investments Australia’s Damora Therapeutics DMRA Stock Holding History

Vanguard Investments Australia’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$241K Buy
+9,279
New +$225K ﹤0.01% 2030

Other funds holding DMRA

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Vanguard Investments Australia's DMRA Position: Q2 2026 in Review

Vanguard Investments Australia opened a new position in Damora Therapeutics (DMRA) in Q2 2026: 9,279 shares worth $241K. The stake represents ﹤0.01% of the portfolio and ranks #2030 among its holdings.

94 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Vanguard Investments Australia held 9,279 shares of Damora Therapeutics worth $241K as of Q2 2026.
  • Damora Therapeutics was a new Vanguard Investments Australia position in Q2 2026.
  • Damora Therapeutics made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2030 holding.
  • 94 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.